SG10202112636SA - Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment - Google Patents
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatmentInfo
- Publication number
- SG10202112636SA SG10202112636SA SG10202112636SA SG10202112636SA SG10202112636SA SG 10202112636S A SG10202112636S A SG 10202112636SA SG 10202112636S A SG10202112636S A SG 10202112636SA SG 10202112636S A SG10202112636S A SG 10202112636SA SG 10202112636S A SG10202112636S A SG 10202112636SA
- Authority
- SG
- Singapore
- Prior art keywords
- combination
- cancer treatment
- chemotherapy agents
- fgfr2 antibodies
- fgfr2
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012829 chemotherapy agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507053P | 2017-05-16 | 2017-05-16 | |
US201762581992P | 2017-11-06 | 2017-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202112636SA true SG10202112636SA (en) | 2021-12-30 |
Family
ID=62567776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202112636SA SG10202112636SA (en) | 2017-05-16 | 2018-05-15 | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
Country Status (10)
Country | Link |
---|---|
US (2) | US11091555B2 (ja) |
EP (1) | EP3624837A1 (ja) |
JP (2) | JP7299842B2 (ja) |
KR (1) | KR20200006538A (ja) |
CN (1) | CN110621336B (ja) |
AU (1) | AU2018269984A1 (ja) |
BR (1) | BR112019023898A2 (ja) |
CA (1) | CA3062177A1 (ja) |
SG (1) | SG10202112636SA (ja) |
WO (1) | WO2018213304A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017091580A1 (en) * | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
CN114846029A (zh) * | 2019-12-24 | 2022-08-02 | 迪哲(江苏)医药股份有限公司 | 新颖抗fgfr2b抗体 |
CN111760026A (zh) * | 2020-08-06 | 2020-10-13 | 汪炬 | FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用 |
KR20230129456A (ko) * | 2020-12-29 | 2023-09-08 | 선전 포워드 파머수티컬즈 코 엘티디 | 항-fgfr2 항체 및 이의 용도 |
TW202342527A (zh) * | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ES2133271T3 (es) | 1989-07-06 | 1999-09-16 | Univ California | Receptores para factores de crecimiento de fibroblastos. |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
AU3494397A (en) | 1996-06-18 | 1998-01-07 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fibroblast growth factor receptor activating gene i and related compositions and methods |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
PT1034298E (pt) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
JP4926320B2 (ja) | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
JP2001302699A (ja) | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトkgfrに対する抗体 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
AU2002339845B2 (en) | 2001-08-03 | 2009-03-26 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
JP2005530687A (ja) | 2002-01-31 | 2005-10-13 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Fgfrアゴニスト |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
KR100493460B1 (ko) | 2002-08-29 | 2005-06-07 | 재단법인서울대학교산학협력재단 | 암 세포에서 발현되는 fgfr2 이성체 |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
PL1680140T3 (pl) | 2003-10-16 | 2011-11-30 | Imclone Llc | Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia |
EP1678314B1 (en) | 2003-10-22 | 2012-09-05 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7872016B2 (en) | 2004-05-25 | 2011-01-18 | Yale University | Method for treating skeletal disorders resulting from FGFR malfunction |
WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
CA2648021A1 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute, Inc. | Prognostic and diagnostic method for cancer therapy |
WO2007134210A2 (en) | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
CA2655246A1 (en) | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
BRPI0717431A2 (pt) | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
WO2008052796A1 (en) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
CL2007003411A1 (es) | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CA2676529C (en) | 2007-01-24 | 2014-03-25 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
BRPI0809137A2 (pt) | 2007-03-23 | 2016-07-26 | Translational Genomics Res Inst | métodos de diagnosticar, câncer endometrial e pré-câncer classificar e tratar |
US20130183288A1 (en) | 2007-03-28 | 2013-07-18 | Biogen Idec Inc. | Non-fucosylated antibodies |
US20110091473A1 (en) | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
WO2012021841A2 (en) | 2010-08-12 | 2012-02-16 | Attogen Inc. | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
US20110059091A1 (en) | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
EP2285984A1 (en) | 2008-06-10 | 2011-02-23 | University Of Southern California | Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients |
EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
EP3783024A1 (en) | 2008-11-07 | 2021-02-24 | Galaxy Biotech, LLC | Monoclonal antibodies to fibroblast growth factor receptor 2 |
US20120301482A1 (en) | 2009-08-25 | 2012-11-29 | National Jewish Health | Methods and compositions for treatment of lung injury |
AU2010313621C1 (en) | 2009-10-14 | 2015-11-26 | Humanigen, Inc. | Antibodies to EphA3 |
SG181850A1 (en) | 2010-01-14 | 2012-08-30 | Univ Yale | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
EP2547698B1 (en) | 2010-03-14 | 2015-07-29 | The Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
JP2013529076A (ja) | 2010-05-11 | 2013-07-18 | アベオ ファーマシューティカルズ, インコーポレイテッド | 抗fgfr2抗体 |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
CN106432506A (zh) * | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
BR112014014763A8 (pt) | 2011-12-14 | 2017-07-04 | Seattle Genetics Inc | novos conjugados de anticorpo-medicamento (adcs) e uso dos mesmos |
SG10201608382QA (en) | 2012-04-09 | 2016-12-29 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
US20150191791A1 (en) | 2012-07-05 | 2015-07-09 | Lsip, Llc | Fgfr2 fusion gene |
WO2014089193A1 (en) | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
CN105188732A (zh) | 2013-05-01 | 2015-12-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
SG11201510210XA (en) | 2013-06-13 | 2016-01-28 | Univ South Australia | Methods for detecting prostate cancer |
PT3027651T (pt) | 2013-08-01 | 2019-05-31 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2iiib não fucosilados |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015116868A2 (en) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
WO2017091580A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
-
2018
- 2018-05-15 CA CA3062177A patent/CA3062177A1/en active Pending
- 2018-05-15 AU AU2018269984A patent/AU2018269984A1/en active Pending
- 2018-05-15 JP JP2019562617A patent/JP7299842B2/ja active Active
- 2018-05-15 EP EP18730518.0A patent/EP3624837A1/en active Pending
- 2018-05-15 WO PCT/US2018/032757 patent/WO2018213304A1/en unknown
- 2018-05-15 SG SG10202112636SA patent/SG10202112636SA/en unknown
- 2018-05-15 BR BR112019023898A patent/BR112019023898A2/pt unknown
- 2018-05-15 US US16/613,579 patent/US11091555B2/en active Active
- 2018-05-15 CN CN201880030376.3A patent/CN110621336B/zh active Active
- 2018-05-15 KR KR1020197033263A patent/KR20200006538A/ko not_active Application Discontinuation
-
2021
- 2021-07-02 US US17/366,580 patent/US20220041737A1/en active Pending
-
2023
- 2023-04-04 JP JP2023060867A patent/JP2023093527A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019141070A (ru) | 2021-06-16 |
JP7299842B2 (ja) | 2023-06-28 |
CA3062177A1 (en) | 2018-11-22 |
JP2020520903A (ja) | 2020-07-16 |
US20200079856A1 (en) | 2020-03-12 |
CN110621336A (zh) | 2019-12-27 |
WO2018213304A1 (en) | 2018-11-22 |
US11091555B2 (en) | 2021-08-17 |
BR112019023898A2 (pt) | 2020-06-09 |
JP2023093527A (ja) | 2023-07-04 |
EP3624837A1 (en) | 2020-03-25 |
RU2019141070A3 (ja) | 2021-09-10 |
US20220041737A1 (en) | 2022-02-10 |
AU2018269984A1 (en) | 2019-12-05 |
CN110621336B (zh) | 2024-05-14 |
KR20200006538A (ko) | 2020-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261395A (en) | Combined treatment with antibodies against cd73 | |
HK1243005A1 (zh) | 抗lilrb抗體及其在檢測和治療癌症中的用途 | |
IL259162B (en) | fgfr2 inhibitors alone or in combination with immunostimulating agents in cancer treatment | |
GB201719076D0 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
IL271221A (en) | Antibodies that bind il-1beta for use in cancer therapy | |
SG10202112636SA (en) | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment | |
SI3423087T1 (sl) | Kombinirana terapija proti raku | |
ZA201804117B (en) | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | |
IL257274B (en) | Preparations and methods for the treatment of cancers related to the activation of the endothelin B receptor. | |
IL263123A (en) | Cancer treatments | |
IL271019A (en) | Tinostemustine for the treatment of ovarian cysts | |
IL260474B (en) | Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment | |
IL258980A (en) | Preparation of bispecific antigens and their use in cancer | |
IL250507A0 (en) | Anti-ck8 antibodies for use in cancer therapy | |
HUE054998T2 (hu) | Kombinációs terápiák emlõrák kezelésében való alkalmazásra | |
ZA202000851B (en) | Antibodies useful in cancer diagnosis | |
IL262143A (en) | Improvements in cancer treatment | |
IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
IL280421A (en) | Cancer treatment by antibody | |
SI3518911T1 (sl) | RAD1901 za uporabo v zdravljenju raka jajčnikov | |
EP3334471C0 (en) | IMPROVED CANCER TREATMENT WITH DOXORUBICINE | |
GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
GB201813138D0 (en) | Cancer treatment with an antibody | |
GB201621692D0 (en) | Anti Cancer Agents |